Brokers Issue Forecasts for Amphastar Pharmaceuticals, Inc.’s FY2024 Earnings (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) – Stock analysts at Capital One Financial lifted their FY2024 earnings per share estimates for shares of Amphastar Pharmaceuticals in a research report issued to clients and investors on Wednesday, April 17th. Capital One Financial analyst T. Chiang now forecasts that the company will post earnings per share of $3.48 for the year, up from their previous estimate of $3.43. The consensus estimate for Amphastar Pharmaceuticals’ current full-year earnings is $3.42 per share.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing the consensus estimate of $0.84 by ($0.03). The business had revenue of $178.11 million for the quarter, compared to analysts’ expectations of $174.90 million. Amphastar Pharmaceuticals had a return on equity of 26.95% and a net margin of 21.34%.

Other equities research analysts have also recently issued research reports about the company. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, April 10th. JPMorgan Chase & Co. initiated coverage on Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 price objective for the company. Finally, StockNews.com cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $66.00.

Amphastar Pharmaceuticals Price Performance

AMPH stock opened at $40.01 on Friday. The business has a 50 day moving average price of $46.27 and a 200 day moving average price of $51.14. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of 15.51, a PEG ratio of 0.96 and a beta of 0.84. Amphastar Pharmaceuticals has a fifty-two week low of $35.62 and a fifty-two week high of $67.66. The company has a quick ratio of 1.70, a current ratio of 2.17 and a debt-to-equity ratio of 0.92.

Insider Activity

In other news, Director Floyd F. Petersen sold 500 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $53.10, for a total value of $26,550.00. Following the transaction, the director now owns 80,333 shares of the company’s stock, valued at $4,265,682.30. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Michael A. Zasloff sold 12,500 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total transaction of $589,750.00. Following the transaction, the director now owns 21,326 shares of the company’s stock, valued at $1,006,160.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Floyd F. Petersen sold 500 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $53.10, for a total value of $26,550.00. Following the transaction, the director now directly owns 80,333 shares in the company, valued at approximately $4,265,682.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 14,000 shares of company stock valued at $660,860. Company insiders own 28.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of AMPH. Exchange Traded Concepts LLC grew its holdings in Amphastar Pharmaceuticals by 0.8% in the fourth quarter. Exchange Traded Concepts LLC now owns 21,440 shares of the company’s stock valued at $1,326,000 after purchasing an additional 169 shares during the last quarter. Quadrant Capital Group LLC grew its holdings in Amphastar Pharmaceuticals by 27.8% in the fourth quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock valued at $63,000 after purchasing an additional 223 shares during the last quarter. Guidance Capital Inc. grew its holdings in Amphastar Pharmaceuticals by 3.9% in the third quarter. Guidance Capital Inc. now owns 7,152 shares of the company’s stock valued at $321,000 after purchasing an additional 267 shares during the last quarter. Bridge City Capital LLC grew its holdings in Amphastar Pharmaceuticals by 0.8% in the first quarter. Bridge City Capital LLC now owns 34,773 shares of the company’s stock valued at $1,527,000 after purchasing an additional 275 shares during the last quarter. Finally, Los Angeles Capital Management LLC grew its holdings in Amphastar Pharmaceuticals by 1.3% in the third quarter. Los Angeles Capital Management LLC now owns 27,443 shares of the company’s stock valued at $1,262,000 after purchasing an additional 358 shares during the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.